US FDA approves Sanofi's wearable injector form of blood cancer drug

The FDA has approved Sarclisa Escena, a wearable subcutaneous form of Sanofi's blood cancer drug, delivering the drug via on-body injector instead of intravenous infusion. The approval reduces patient treatment burden and clinic capacity strain while giving Sanofi a regulatory win under new leadership.

This Wire brief sits within Fusion42's coverage of Digital Health.